The US FDA has approved REMS* for armodafinil [Nuvigil] and modafinil [Provigil] tablets

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2010年 / 1325卷 / 1期

关键词：

Public Health; Paediatric Patient; Potential Risk; Risk Evaluation; Modafinil;

D O I：

10.2165/00128415-201013250-00010

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 9 条

[1] The US FDA has approved a single shared REMS* for the transmucosal immediate-release fentanyl
Reactions Weekly, 2012, 1384 (1) : 3 - 3
[2] The US FDA has updated the REMS* for both romiplostim [Nplate] and eltrombopag [Promacta]
Reactions Weekly, 2011, 1382 (1) : 5 - 5
[3] The US FDA has approved Abraxane (R) for the treatment of non-small-cell lung cancer
Attwood, Claire
LUNG CANCER MANAGEMENT, 2012, 1 (04) : 251 - 251
[4] The US FDA has approved additional changes to the label for the Ortho Evra Contraceptive Transdermal (Skin) Patch
Reactions Weekly, 2008, 1186 (1) : 3 - 3
[5] The efficacy or safety profile of Provigil (Modafinil) tablets in patients with and without cataplexy: Results from two US multicenter, double-blind, randomized, placebo-controlled trials
Hirshkowitz, M
Ristanovic, R
Vadiei, K
ANNALS OF NEUROLOGY, 1999, 46 (03) : 494 - 494
[6] The US FDA has approved changes to the US labels of the erectile dysfunction therapies Cialis [tadalafil], Levitra [vardenafil] and Viagra [sildenafil]
Reactions Weekly, 2007, 1175 (1) : 2 - 2
[7] Following Ranbaxy's recall of atorvastatin tablets,* the US FDA says it has reviewed additional information
Reactions Weekly, 2012, 1431 (1) : 3 - 3
[8] The US FDA has finalised revisions to the Ketek [telithromycin] label, which include removing two of the three previously approved indications
Reactions Weekly, 2007, 1139 (1) : 3 - 3
[9] IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US: HAS IT MADE A DIFFERENCE?
Mordin, M.
Clark, M.
Siersma, C.
Copley-Merriman, K.
Gnanasakthy, A.
VALUE IN HEALTH, 2009, 12 (03) : A29 - A29